CTOs on the Move


 
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class - while empowering our community to take control of diabetes.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.dexcom.com
  • 6340 Sequence Drive
    San Diego, CA USA 92121
  • Phone: 888.738.3646

Executives

Name Title Contact Details
Shelly Selvaraj
Senior Vice President of Information Technology Profile
Jacob Leach
Chief Technology Officer Profile
Jacob Leach
Executive Vice President, Chief Technology Officer and Chief Operating Officer Profile
John Iraci
Director, IT Infrastructure and Operations Profile

Similar Companies

CardioFocus

CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF).

DCI International

DCI International is a Newberg, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sterilis Inc

Sterilis Inc is a Fountain Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North American Medical Management

For over a decade, NAMM California has championed physician driven medical groups resulting in superior quality health care for patients. North American Medical Management, California (NAMM California) develops and manages medical groups providing a

Shockwave Medical

Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotrispy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. In peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, IVL demonstrated safety and consistent procedure success with low procedural complications. The technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatments. And because it is built on a traditional balloon catheter platform, it integrates seamlessly with clinicians` existing workflow.